Search results
Added:
3 years ago
Aim: New antidiabetic drugs are required to be evaluated in cardiovascular outcome trials (CVOTs). Few of these are direct comparisons between new drugs, so we performed a network meta-analysis to compare the new drug classes in terms of cardiovascular outcomes.
Method: We searched for CVOTs involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2)…
View more
Added:
3 years ago
Added:
3 years ago
Added:
9 months ago
Added:
3 years ago
Type 2 diabetes (T2D) remains a major cardiovascular (CV) risk factor1–5 and it confers an approximately two- to threefold fold excess risk for coronary heart disease, including MI, stroke and heart failure (HF) in patients with and in patients without established cardiovascular disease (CVD).1,6–8 The prevalence of T2D among patients with HF is as high as 40–45% and that of HF in patients with…
View more
Added:
2 years ago
Added:
3 years ago
Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop…
View more
Added:
3 years ago
Added:
3 years ago
Hypertension affects approximately 26% of adults globally and is a leading risk factor for cardiovascular disease and death. The renin system is central to blood pressure (BP) control, and chronic activation of the system, as occurs in pathological conditions, leads to damage to organs (such as the heart and kidneys), as well as perpetuating elevated BP. Identification of the pivotal role played…
View more
Added:
2 years ago
